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ABSTRACT:
Introduction: Metabolic syndrome is defined as the presence of at least 3 of the following parameters: (1) waist 
circumference ≥ 90 cm, (2) triglycerides > 150 mg/dl or treatment for hypertriglyceridemia, (3) HDL-cholesterol 
< 40 mg/dl or treatment for reduced HDL-cholesterol, (4) blood pressure ≥ 130/85 mmHg or current use of 
antihypertensive medications, (5) fasting blood glucose ≥ 110 mg/dl or previous diagnosis of type-2 diabetes 
mellitus. It is closely associated with many diseases and  recent studies have also shown its association with 
benign prostatic hyperplasia and lower urinary tract symptoms. Our study aimed to investigate association between 
metabolic syndrombe and its components with benign prostatic hyperplasia among patients managed surgically in 
a tertiary centre in Western Nepal. Methods: One hundred and four patients above 50 years with benign prostatic 
hyperplasia managed in the department of Surgery over one year were included in the study. Results: Twenty-seven 
patients had metabolic syndrome (25.96%). There was association between metabolic syndrome and mean prostate 
size and among components of metabolic syndrome, high serum triglyceride and low HDL Cholesterol were 
found to be associated. There was increase in mean prostate size with increase in number of metabolic syndrome 
components which was statistically significant. Conclusion: Metabolic syndrome along with its two components, 
serum triglyceride and HDL Cholesterol were associated with increase in mean prostate size. 
Keyword: benign prostatic hyperplasia, lower urinary tract symptoms, metabolic syndrome, triglycerides 
——————————————————————————————————————————————
J. Lumbini. Med. Coll. Vol 6, No 2, July-Dec 2018
Original Articlehttps://doi.org/10.22502/jlmc.v6i2.207
___________________________
Submitted: 26 January 2018
Accepted: 24 June 2018
Published: 18 July 2018
a - Associate Professor
b - Lecturer
c - Assistant Professor
d - Department of Surgery, Lumbini Medical College, Palpa, Nepal
Corresponding Author:
Raj Kumar Chhetri
e-mail: chhetrirkcdr@gmail.com
ORCID: https://orcid.org/0000-0002-3123-2053
How to cite this article:
Chhetri RK, Baral S, Thapa N. Metabolic syndrome and benign 
prostatic hyperplasia: A Nepalese perspective. Journal of Lumbini 
Medical College. 2018;6(2):4 pages. DOI: 10.22502/jlmc.v6i2.207. 
Epub: 2018 July 18.  
Licensed under CC BY 4.0 International License which permits use, distribution 
and reproduction in any medium, provided the original work is properly cited.____________________________
INTRODUCTION:
 Metabolic syndrome (MetS) is a clinical 
terminology which was proposed by the American 
endocrinologist Gerald Reaven in 1988.[1] It is 
a cluster of biological factors characterized by 
atherogenic dyslipidemia, hypertension, disrupted 
glucose metabolism and obesity. These all contribute 
to an increased risk of cardiovascular disease and 
type 2 diabetes mellitus.[2]
	 MetS	was	defined	by	the	National	Cholesterol	
Education Program-Third Adult Treatment Panel 
(NCEP-ATPIII)	United	States	as	presence	of	at	least	
three of the following parameters:[3]
1. Waist	circumference	≥	90	cm
2. Triglycerides > 150 mg/dl or treatment for 
hypertriglyceridemia
3. High	density	lipoprotein-cholesterol	(HDL-C)	
<	40	mg/dl	or	treatment	for	reduced	HDL-C
4. Blood	pressure	≥	130/85	mmHg	or	current	use	
of antihypertensive medications
5. Fasting	blood	glucose	≥	110	mg/dl	or	previous	
diagnosis of type 2 diabetes mellitus
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 As per the International Diabetic Federation 
2005 criteria for detection of MetS among Indian 
subcontinent population, waist circumference in 
males	≥90	cm	was	considered	as	central	obesity.(4)	
Various epidemiological studies have shown that 
about 25% of middle-aged people in high-income 
countries have the symptoms of MetS. Benign 
prostatic hyperplasia (BPH) has now assumed the 
status of global epidemic owing to its socio-economic 
implications and the increasing incidence.[4] 
 The incidence of BPH increases with the age 
of patients which is now the most common disease 
in the elderly. Prostatic hyperplasia is seen in around 
20% of men in the fourth decade of life, which 
increases to approximately 80% after 80 years of 
age.[5] Ever since the study done by Hammarsten 
J. in 1998 about the components of MetS and the 
risk for the development of BPH there are many 
studies trying to establish their relationship with 
varying results.[4,6,7,8] Though the relationship 
between Benign Prostatic Hyperplasia/Lower 
Urinary	 Tract	 Symptoms	 (BPH/LUTS)	 and	 MetS	
is not well understood, studies have suggested that 
men with MetS have more rapid growth of prostate 
as compared to those without MetS.[9]
 According to the census of Lumbini Medical 
College	 and	 Teaching	 Hospital	 (LMCTH),	 LUTS	
and BPH are the most common causes for elderly 
men to visit the surgical Outpatient Department 
(OPD)  second only to urinary stone disease. It is 
also seen that many a times operations are postponed 
or cancelled either due to raised blood pressure 
(BP), hyperglycaemia or other cardiovascular 
comorbidities. We, therefore, conducted this study 
to analyze the relationship between BPH and MetS 
and its components.
METHODS:
 This is an observational, cross-sectional, 
analytical study conducted in the Department 
of	 Surgery	 of	 LMCTH,	 Palpa,	 Nepal.	 The	 study	
protocol was approved by Institutional Review 
Committee	 	 of	 the	 institute.	 The	 study	 was	 done	
from 1st  January 2017 to 31st December 2017 over 
one	year.	A	proforma	was	designed	and	it	was	filled	
up with the help of surgical residents. All the male 
patients above 50 years of age operated in surgery 
department with BPH diagnosed clinically by 
digital	rectal	examination,	Prostate	specific	antigen	
estimation and by ultrasound evaluation were 
included in the study. The criteria for metabolic 
syndrome comprised of at least three of the 
components	 as	 defined	 by	 the	 NCEP-ATPIII.[4]	
The study population was divided into two groups: 
MetS group and the non-MetS group. Patients below 
50 years of age were managed medically, so were 
not included in this study. Patients with prostatic or 
urinary	 bladder	 malignancy	 diagnosed	 with	 USG,	
PSA and cystoscopy   were excluded from the study.
The grading of the prostate gland enlargement 
was done on the basis of clinical assessment and 
ultrasound	findings	as:[10]
1. Grade - I: prostate size of  21-30 cc
2. Grade - II: prostate size of 31-50 cc
3. Grade - III: prostate size of 51-80 cc
4. Grade - IV: prostate size of  > 80 cc
 Body mass index (BMI) is calculated as 
weight in kilograms divided by the square of the 
height in meters (kg/m2) and is categorized into four 
groups	according	 to	 the	National	Heart,	Lung,	and	
Blood	 Institute	 (NHLBI),	 with	 the	 Asian-Pacific	
cutoff	points	as:[11]
1. underweight: less than 18.5 kg/m2
2. normal weight: 18.5 – 22.9 kg/m2
3. overweight: 23 – 24.9 kg/m2
4. obese:	≥	25	kg/m2
 International Prostate Symptom score (IPSS) 
was	 determined	 in	 every	 patient	 and	 classified	 as	
mild, moderate and severe with the scores of 0 to 7, 
8 to 19 and 20 to 35 respectively.[4]  
 All statistical analyses were performed using 
SPSS	 version	 20	 (SPSS	 Inc.,	 Chicago,	 Ill.,	USA).	
Descriptive data are presented as mean and standard 
deviation (SD) for continuous data. Age was   divided 
into four categories : 51-60, 61-70, 71-80 and more 
than	80	years.	 	The	Chi-square,	Student-	 t	 test	and	
one	 way	 ANOVA	 tests	 were	 used	 as	 applicable	
to	 compare	 differences	 between	 the	 variables	
between the subjects with and without MetS. In all 
comparisons, p values < 0.05 were considered to be 
statistically	significant.
RESULTS:
 There were total 110 patients who were 
operated with diagnosis of BPH, however the 
histopathology report of six patients came as prostatic 
carcinoma and were excluded from the study. So, 
104 patients were included in the study who met  the 
inclusion criteria. Among these patients 56.7% (n = 
59) had grade three prostatomegaly and 90.4% (n = 
94) had severe IPSS score. Amongst 104 patients, 
25.96%	 (n	=	 27)	 had	MetS.	Ninety	 seven	patients	
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had BMI < 25 (93.2%) and none of the patients were 
obese. Table 1 shows that there is an increase in 
mean  prostate size as the age of the patient increases. 
However	this	finding	was	not	statistically	significant	
(F = 0.388, df = 3 ,  p = 0.762).
 Among the components of MetS, serum 
triglyceride	 (p	 =	 0.005)	 	 and	 HDL	Cholesterol	 (p	
= 0.002) were found to be associated with increase 
in mean prostate size in the comparative analysis 
of individual components of MetS with the mean 
prostate size (Table 2). 
 It was found that as the number of 
components of MetS increased from zero to two, 
there was no increase in mean prostate size (Table 
3). However from two onwards, there was increase 
in mean prostate size which was statistically highly 
significant	(F=7.65,	df=4,	p<0.001)	.
 It was also seen from Table 4 that the mean 
prostate size was higher in patients with MetS which 
was	statistically	significant.	(t=	-5.437,	df=	102,	p=	
0.0001) 
 Table 5 shows that mean prostate grade was 
higher in patients with MetS which was statistically 
significant	(t=-2.983,	df=102,	P=0.004)	
DISCUSSION:
 The incidence of BPH increases with the age 
of patients which is now the most common disease 
in the elderly. Prostatic hyperplasia is seen in around 
20% of men in the fourth decade of life, which 
increases to approximately 80% after 80 years of age.
[5] Various literatures have shown the relationship 
between the components of MetS with BPH, and 
the patients with the syndrome show increase in the 
mean size of prostate with the increase in the age 
of the patient.[13] The objective of our study was 
to	 find	whether	 there	was	 association	 between	 the	
MetS and its components with BPH.
 In our study, out of 104 patients with BPH, 
90.4% (n = 94) had severe IPS score and 97 of them 
had BMI < 25 (93.2%) but none were obese. A study 
conducted	by	Nandy	PR.	and	Saha	S.	in	India	found	
all patients had moderate to severe IPS score while 
34% were overweight and 7.8% were obese.[4]
 Twenty seven (26%) patients in our study 
had MetS and mean prostate size increased as the 
age	 increased	 though	 not	 statistically	 significant.	
A study conducted by Yeon Won Park from Korea 
noted MetS  in 29% of patients.[14] Similarly, 
Table 1: Mean prostate size according to age group (n = 104)
Age Group 
(years) n %
mean (SD)
cc p
51 - 60 22 21.2 56.55 (11.31)
0.76
61 - 70 26 25 59.77 (16.9)
71 - 80 46 44.2 59.52 (14.19)
> 80 10 9.6 62.3 (20.47)
Table 2: Prostate size and its association with metabolic
              syndrome components (n=104)
Metabolic syndrome 
components n mean±SD p
Serum Triglyceride 
(mg/dl)
>150 34 65.09±15.22
0.005
<150 70 56.37±14.05
HDL	Cholesterol	
(mg/dl)
<40 37 65.27±13.53
0.002
>40 67 55.94±14.70
Fasting blood sugar 
(mg/dl)
>110 33 62.82±14.40
0.094
<110 71 57.55±14.96
Blood pressure 
(mmHg)
>130/85 32 59.94±17.15
0.75
<130/85 72 58.90±17.15
Waist circumference 
(cm)
<90 58 58.97±15.26
0.85
>90 46 59.54±14.64
Table 3: Association between components of metabolic 
              syndrome and mean prostate size (n=104)
Metabolic syndrome
components n
mean±SD 
cc p
0 17 56.59±16.21
<0.001
1 26 56.38±12.35
2 34 53.26±13.13
3 21 70.29±13.15
4 6 74±8.39
Table 4: Association of metabolic syndrome with mean                    
              prostate size (n=104)
Metabolic Syndrome n mean±SD in cc p
Present 27 71.11±12.21
<0.001
Absent 77 55.05±13.52
Table 5: Association of metabolic syndrome with mean
              prostate grade (n=104)
Metabolic Syndrome n Prostate Grade (Mean± SD) p
Present 27 3.04±0.52
0.004
Absent 77 2.64±0.63
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studies	 from	 China	 showed	 MetS	 was	 associated	
with higher prostatic volume and higher annual 
growth rate.[7]
 Our study showed  association between 
the MetS and mean prostate size. High serum 
triglyceride and low HDL cholesterol were found to 
be associated with the mean prostate size which was 
statistically	 significant.	DiBello	 JR.	 et	 al.	 in	 a	UK	
based cross-sectional epidemiological study found 
that 26.5% of patients with BPH had MetS and 
significantly	 larger	 prostate	 was	 found	 in	 patients	
who had MetS.[8] As the number of components of 
MetS increased there was increase in mean prostate 
size	 which	 was	 statistically	 highly	 significant.	
Hammarsten	J.	 in	his	paper,	which	was	the	first	of	
its kind, also found that the prostate gland was larger 
in men with components of MetS.[6] Other studies 
also	 found	 similar	 results.[3,15,16]	 Nandy	 PR.	 in	
his study found that the MetS and its components 
except the waist circumference had association with 
prostate	 volume.[4]	 Similarly,	 studies	 from	 China	
found	that	MetS,	BMI,	low	HDL-C	were	considered	
risk factors for prostatic enlargement.[7,17] Other 
meta-analysis and multicentre studies showed higher 
MetS among BPH patients (36 to 60%) and MetS 
and its components were associated with prostate 
volume.[2,5,9,15,18] However, Yeon Won Park  did 
not	 find	 any	 association	 between	 BPH/LUTS	 and	
metabolic syndrome.[14]
CONCLUSION:
 Mean prostate size and grade were 
significantly	 larger	 in	 patients	 with	 metabolic	
syndrome. Among the components of metabolic 
syndrome, high serum triglyceride and low HDL 
cholesterol were associated with BPH. Therefore, 
there is an association between metabolic syndrome 
and some of its components with BPH.
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